Ideas

Lifespan- and healthspan-extension therapy: Snai1/Snail, a protein that promotes epithelial to mesenchymal transition, may increase life span via up-regulation of its target gene BubR1 and others, 3/June/2018, 11.00 pm
Lifespan- and healthspan-extension therapy: Snai1/Snail, a protein that promotes epithelial to mesenchymal transition, may increase life span via up-regulation of its target gene BubR1 and others, 3/June/2018, 11.00 pm 960 720 Dr Boomi's Genom-2-Discovery Center

 What they say: Introduction:  A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School…

read more

Unknown action of a known drug in rescuing blood sugar disease: Bromocriptine-based adjunct therapy for autoimmune diabetes (TIDM): Bromocriptine (trade name:Parlodel), used in the treatment of  pituitary tumors, Parkinson’s disease (PD), hyperprolactinaemia, infertility and others, increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene, 3/June/2018, 7.32 pm
Unknown action of a known drug in rescuing blood sugar disease: Bromocriptine-based adjunct therapy for autoimmune diabetes (TIDM): Bromocriptine (trade name:Parlodel), used in the treatment of  pituitary tumors, Parkinson’s disease (PD), hyperprolactinaemia, infertility and others, increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene, 3/June/2018, 7.32 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical Sciences, University of Milan, Milan…

read more

Locking blood sugar disease with an interleukin therapy: Interleukin(IL-2)-based therapy for TIIDM: IL-2 increases the expression of IGF1R, INSR, and IRS2, and promotes an insulin-sensitized state, via up-regulation of  its target gene Lin28, 1/June/2018, 11.23 pm
Locking blood sugar disease with an interleukin therapy: Interleukin(IL-2)-based therapy for TIIDM: IL-2 increases the expression of IGF1R, INSR, and IRS2, and promotes an insulin-sensitized state, via up-regulation of  its target gene Lin28, 1/June/2018, 11.23 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say:   A study from the Stem Cell Transplantation Program, Division of Pediatric Hematology/Oncology, Boston Children’s Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts, USA shows that “The Lin28/let-7 axis regulates glucose metabolism.” This study…

read more

Unknown action of a known drug in body weight control, energy homeostasis and TIIDM:Bromocriptine (trade name:Parlodel), used in the treatment of  pituitary tumors, Parkinson’s disease (PD), hyperprolactinaemia, infertility and others, increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 1/June/2018, 11.14 pm
Unknown action of a known drug in body weight control, energy homeostasis and TIIDM:Bromocriptine (trade name:Parlodel), used in the treatment of  pituitary tumors, Parkinson’s disease (PD), hyperprolactinaemia, infertility and others, increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 1/June/2018, 11.14 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458, USA shows that “Regulation of circadian behaviour and metabolism by synthetic…

read more

Combinatorial therapy for cardiomyocyte proliferation and heart regeneration: A pharmaceutical mixture encompassing L-Malate, Lithium and Imidazopyridine derivative (X22) (MLX22) decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up regulation of its target gene, 1/June/2018, 10.51 pm
Combinatorial therapy for cardiomyocyte proliferation and heart regeneration: A pharmaceutical mixture encompassing L-Malate, Lithium and Imidazopyridine derivative (X22) (MLX22) decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up regulation of its target gene, 1/June/2018, 10.51 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA; Key Laboratory of Molecular Target and…

read more

Locking blood sugar disease with an interleukin therapy: Interleukin(IL-15)-based therapy for TIIDM: IL-15 increases the expression of IGF1R, INSR, and IRS2, and promotes an insulin-sensitized state, via up-regulation of  its target gene Lin28, 1/May/2018, 10.33 pm
Locking blood sugar disease with an interleukin therapy: Interleukin(IL-15)-based therapy for TIIDM: IL-15 increases the expression of IGF1R, INSR, and IRS2, and promotes an insulin-sensitized state, via up-regulation of  its target gene Lin28, 1/May/2018, 10.33 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say:   A study from the Stem Cell Transplantation Program, Division of Pediatric Hematology/Oncology, Boston Children’s Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts, USA shows that “The Lin28/let-7 axis regulates glucose metabolism.” This study…

read more
Start Typing